medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/2079-701X-2019-10-10-14medsovet-3047Research ArticleИММУНОТЕРАПИЯ В ОНКОЛОГИИImmunotherapy in oncologyПсевдопрогрессирование на фоне иммунотерапииPseudoprogression in patients on immunotherapyhttps://orcid.org/0000-0002-0620-2696ЮдинД. И.YudinD. I.

к.м.н., старший научный сотрудник отделения клинических биотехнологий Федерального государственного бюджетного учреждения «Национальный медицинский исследовательский центр онкологии имени Н.Н. Блохина» Министерства здравоохранения Российской Федерации.

Cand. of Sci. (Med), Senior Researcher at the Clinical Biotechnologies Department of the Federal State Budgetary Institution «Blokhin Russian Cancer Research Center» of the Ministry of Health of the Russian Federation.

yudinden@mail.ruЛактионовК. К.LaktionovK. K.

д.м.н., заместитель директора по лечебной работе Научно-исследовательского института клинической онкологии, заведующий отделением химиотерапии № 1 торакоабдоминального отдела (клинических биотехнологий) Федерального государственного бюджетного учреждения «Национальный медицинский исследовательский центр онкологии имени Н.Н. Блохина» Министерства здравоохранения Российской Федерации.

Dr. of Sci. (Med), Deputy Director for Medical Work of the Research Institute of Clinical Oncology, Head of the Department of Chemotherapy No. 1 of the Thoracoabdominal Department (Clinical Biotechnologies) of the Federal State Budgetary Institution «Blokhin Russian Cancer Research Center» of the Ministry of Health of the Russian Federation.

lkoskos@mail.ruСаранцеваК. А.SarantsevaK. A.

к.м.н., врач-онколог Федерального государственного бюджетного учреждения «Национальный медицинский исследовательский центр онкологии имени Н.Н. Блохина» Министерства здравоохранения Российской Федерации.

Cand. of Sci. (Med), oncologist of the Federal State Budgetary Institution «Blokhin Russian Cancer Research Center» of the Ministry of Health of the Russian Federation.

sarantsevaka@gmail.comБредерВ. В.BrederV. V.

д.м.н., ведущий научный сотрудник отделения химиотерапии № 1 торакоабдоминального отдела (клинических биотехнологий) Федерального государственного бюджетного учреждения «Национальный медицинский исследовательский центр онкологии имени Н.Н. Блохина» Министерства здравоохранения Российской Федерации.

Dr. of Sci. (Med), Leading Researcher of the Department of Chemotherapy No. 1 of the Thoracoabdominal Department (Clinical Biotechnologies) of the Federal State Budgetary Institution «Blokhin Russian Cancer Research Center» of the Ministry of Health of the Russian Federation.

vbreder@yandex.ruРеутоваЕ. В.ReutovaE. V.

к.м.н., старший научный сотрудник хирургического отделения № 13 (клинических биотехнологий) Федерального государственного бюджетного учреждения «Национальный медицинский исследовательский центр онкологии имени Н.Н. Блохина» Министерства здравоохранения Российской Федерации.

Cand. of Sci. (Med), Senior Researcher at the Surgical Department No. 13 (Clinical Biotechnologies) of the Federal State Budgetary Institution «Blokhin Russian Cancer Research Center» of the Ministry of Health of the Russian Federation.

БорисоваО. И.BorisovaO. I.

врач-онколог Федерального государственного бюджетного учреждения «Национальный медицинский исследовательский центр онкологии имени Н.Н. Блохина» Министерства здравоохранения Российской Федерации.

Oncologist of the Federal State Budgetary Institution «Blokhin Russian Cancer Research Center» of the Ministry of Health of the Russian Federation.

dr_borisova@mail.ruАрдзинбаМ. С.ArdzinbaM. S.

к.м.н., врач-онколог, Федеральное государственное бюджетное учреждение «Национальный медицинский исследовательский центр онкологии имени Н.Н. Блохина» Министерства здравоохранения Российской Федерации.

Cand. of Sci. (Med), Oncologist, Federal State Budgetary Institution «Blokhin Russian Cancer Research Center» of the Ministry of Health of the Russian Federation.

merabii@mail.ruФедеральное государственное бюджетное учреждение «Национальный медицинский исследовательский центр онкологии имени Н.Н. Блохина» Министерства здравоохранения Российской Федерации.РоссияFederal State Budgetary Institution «Blokhin Russian Cancer Research Center» of the Ministry of Health of the Russian Federation.Russian Federation2019220620190101014Copyright © Юдин Д.И., Лактионов К.К., Саранцева К.А., Бредер В.В., Реутова Е.В., Борисова О.И., Ардзинба М.С., 20192019Юдин Д.И., Лактионов К.К., Саранцева К.А., Бредер В.В., Реутова Е.В., Борисова О.И., Ардзинба М.С.Yudin D.I., Laktionov K.K., Sarantseva K.A., Breder V.V., Reutova E.V., Borisova O.I., Ardzinba M.S.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/3047

В настоящий момент растет число пациентов, получающих иммунотерапию ингибиторами контрольных точек. Вместе с этим все чаще клиницисты встречают такой клинический феномен, как псевдопрогрессирование. Рентгенологические признаки псевдопрогрессирования отсутствуют. Каждый такой случай требует индивидуального решения.

Now the number of patients receiving immunotherapy with checkpoint inhibitors is growing. At the same time, clinicians increasingly encounter such a clinical phenomenon as pseudoprogression. Nowadays we have no radiological evidences of pseudoprogression. The every such case requires an individual decision.

псевдопрогрессированиеиммунотерапияPD-1антиPD-1/PD-L1pseudoprogressionimmunotherapyанти-CTLA4анти-PD-L1anti PD-1ReferencesChiou V.L., Burotto M. Pseudoprogression and Immune-Related Response in Solid Tumors. J Clin Oncol. 2015 Nov 1;33(31):3541-3.Chiou V.L., Burotto M. Pseudoprogression and Immune-Related Response in Solid Tumors. J Clin Oncol. 2015 Nov 1;33(31):3541-3.Eisenhauer E.A., Therasse P., Bogaerts J. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer. 2009 Januar;45(2):228–47.Eisenhauer E.A., Therasse P., Bogaerts J. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer. 2009 Januar;45(2):228–47.Wolchok J.D., Hoos A., Bohnsack O. et al. Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Wolchok J.D., Hoos A., Bohnsack O. et al. Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria. Clin Cancer Res. 2009;15(23) December 1, 2009.Related Response Criteria. Clin Cancer Res. 2009;15(23) December 1, 2009.Nishino M., Gargano M., Suda M., Ramaiya N.H., Hodi F.S. Optimizing immune-related tumor response assessment: does reducing the number of lesions impact response assessment in melanoma patients treated with ipilimumab? J Immuno ther Cancer. 2014; 2: 17. doi:10.1186/2051-1426-2-17.Nishino M., Gargano M., Suda M., Ramaiya N.H., Hodi F.S. Optimizing immune-related tumor response assessment: does reducing the number of lesions impact response assessment in melanoma patients treated with ipilimumab? J Immuno ther Cancer. 2014; 2: 17. doi:10.1186/2051-1426-2-17.Nishino M. et al. Developing a common language for tumor response to immunotherapy: immune-related response criteria using unidimensional measurements. Clin Cancer Res. 2013 Jul 15;19(14):3936-43.Nishino M. et al. Developing a common language for tumor response to immunotherapy: immune-related response criteria using unidimensional measurements. Clin Cancer Res. 2013 Jul 15;19(14):3936-43.Nishino M., Ramaiya N.H., Chambers E.S. et al. Immune-related response assessment during PD-1 inhibitor therapy in advanced non-small-cell lung cancer patients. J Immunother Cancer. 2016;4:84.Nishino M., Ramaiya N.H., Chambers E.S. et al. Immune-related response assessment during PD-1 inhibitor therapy in advanced non-small-cell lung cancer patients. J Immunother Cancer. 2016;4:84.Seymour L., Bogaerts J., Perrone A. et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 2017;18:e143–52.Seymour L., Bogaerts J., Perrone A. et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 2017;18:e143–52.Hodi F., Ballinger M., Lyons B. et al. Immune- Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy. J Clin Oncol. 2018;36:850-858.Hodi F., Ballinger M., Lyons B. et al. Immune- Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy. J Clin Oncol. 2018;36:850-858.Brahmer J.R., Tykodi S.S., Chow L.Q. et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366:2455–2465Brahmer J.R., Tykodi S.S., Chow L.Q. et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366:2455–2465Topalian S.L., Hodi F.S., Brahmer J.R. et al. Safety, activity, and immune correlates of anti- PD-1 antibody in cancer. N Engl J Med. 2012;366:2443–2454.Topalian S.L., Hodi F.S., Brahmer J.R. et al. Safety, activity, and immune correlates of anti- PD-1 antibody in cancer. N Engl J Med. 2012;366:2443–2454.Topalian S.L., Sznol M., McDermott D.F. et al. Survival, durable tumor remission, and longterm safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol. 2014;32:1020–1030.Topalian S.L., Sznol M., McDermott D.F. et al. Survival, durable tumor remission, and longterm safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol. 2014;32:1020–1030.Wolchok J.D., Kluger H., Callahan M.K. et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013;369:122–133.Wolchok J.D., Kluger H., Callahan M.K. et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013;369:122–133.Hodi F.S., Ribas A., Daud A. et al. Evaluation of immune-related response criteria (irRC) in patients (pts) with advanced melanoma (MEL) treated with the anti-PD-1 monoclonal antibody MK-3475. J Clin Oncol. 2014;(suppl 15s):32. abstr 3006.Hodi F.S., Ribas A., Daud A. et al. Evaluation of immune-related response criteria (irRC) in patients (pts) with advanced melanoma (MEL) treated with the anti-PD-1 monoclonal antibody MK-3475. J Clin Oncol. 2014;(suppl 15s):32. abstr 3006.Wolchok J.D., Hamid O., Ribas A. Atypical patterns of response in patients (pts) with metastatic melanoma treated withpembrolizumab (MK-3475) in KEYNOTE-001. J Clin Oncol. 2015;33(15 supplement):3000. doi: 10.1200/jco.2015.33.15_suppl.3000.Wolchok J.D., Hamid O., Ribas A. Atypical patterns of response in patients (pts) with metastatic melanoma treated withpembrolizumab (MK-3475) in KEYNOTE-001. J Clin Oncol. 2015;33(15 supplement):3000. doi: 10.1200/jco.2015.33.15_suppl.3000.Nishino M., Dahlberg S., Adeni A. et al. Tumor Response Dynamics of Advanced Non–small Cell Lung Cancer Patients Treated with PD-1 Inhibitors: Imaging Markers for Treatment Outcome. Clin Cancer Res. 2017 October 1;23(19). doi: 10.1158/1078-0432.CCR-17-1434.Nishino M., Dahlberg S., Adeni A. et al. Tumor Response Dynamics of Advanced Non–small Cell Lung Cancer Patients Treated with PD-1 Inhibitors: Imaging Markers for Treatment Outcome. Clin Cancer Res. 2017 October 1;23(19). doi: 10.1158/1078-0432.CCR-17-1434.Gettinger S.N., Horn L., Gandhi L., Spigel D.R., Antonia S.J., Rizvi N.A. et al. Overall survival and long-term safety of nivolumab (Anti- Programmed Death 1 Antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol. 2015;33: 2004–12.Gettinger S.N., Horn L., Gandhi L., Spigel D.R., Antonia S.J., Rizvi N.A. et al. Overall survival and long-term safety of nivolumab (Anti- Programmed Death 1 Antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol. 2015;33: 2004–12.Grierson P., Crites D., Ruzinova M. et al. Distinct Clinical and Magnetic Resonance Features of Metastatic Hepatocellular Carcinoma Treated With Pembrolizumab: A Case Report of Late Response After Pseudoprogression. Hepatology Communications. 2018;2:148-151.Grierson P., Crites D., Ruzinova M. et al. Distinct Clinical and Magnetic Resonance Features of Metastatic Hepatocellular Carcinoma Treated With Pembrolizumab: A Case Report of Late Response After Pseudoprogression. Hepatology Communications. 2018;2:148-151.Sweis R., Zha Y. et al. Pseudoprogression manifesting as recurrent ascites with anti-PD-1 immunotherapy in urothelial bladder cancer. Journal for ImmunoTherapy of Cancer. 2018;6:24. doi: 10.1186/s40425-018-0334-x.Sweis R., Zha Y. et al. Pseudoprogression manifesting as recurrent ascites with anti-PD-1 immunotherapy in urothelial bladder cancer. Journal for ImmunoTherapy of Cancer. 2018;6:24. doi: 10.1186/s40425-018-0334-x.Kolla B.C., Patel M.R. Recurrent pleural effusions and cardiac tamponade as possible manifestations of pseudoprogression associated with nivolumab therapy – a report of two cases. J Immunother Cancer. 2016;4:80.Kolla B.C., Patel M.R. Recurrent pleural effusions and cardiac tamponade as possible manifestations of pseudoprogression associated with nivolumab therapy – a report of two cases. J Immunother Cancer. 2016;4:80.

The authors declare that there are no conflicts of interest present.